Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies

Fung, Anne E.; Palanki, Ram; Bakri, Sophie J.; Depperschmidt, Eric E.; Gibson, Andrea

doi:10.1016/j.ophtha.2008.09.014

Cited by 77 publications

(61 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Owing to the rarity of the CNV conditions described, we did not limit our study to only those that met the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement writing standards. 85 Consequently, this review examined all possible published reports, and included case series on small numbers of patients, with variable follow-up periods. Our aim was to report trends and that would be relevant to the treatment of patients with these rare diseases.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

show abstract

“…The use of the recommendations has influenced the style of reporting (Fung et al . 2009). However, there is evidence of misuse (da Costa et al .…”

Section: Introductionmentioning

confidence: 99%

Strengthening the Reporting of Observational Studies in Epidemiology – nutritional epidemiology (STROBE‐nut): An extension of the STROBE statement

et al. 2016

View full text Add to dashboard Cite

Concerns have been raised about the quality of reporting in nutritional epidemiology. Research reporting guidelines such as the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement can improve quality of reporting in observational studies. Herein, we propose recommendations for reporting nutritional epidemiology and dietary assessment research by extending the STROBE statement into Strengthening the Reporting of Observational Studies in Epidemiology – Nutritional Epidemiology (STROBE‐nut). Recommendations for the reporting of nutritional epidemiology and dietary assessment research were developed following a systematic and consultative process, co‐ordinated by a multidisciplinary group of 21 experts. Consensus on reporting guidelines was reached through a three‐round Delphi consultation process with 53 external experts. In total, 24 recommendations for nutritional epidemiology were added to the STROBE checklist. When used appropriately, reporting guidelines for nutritional epidemiology can contribute to improve reporting of observational studies with a focus on diet and health.

show abstract

“…Thus the basis of such clinical practice in this particular circumstance is not based on the highest quality of clinical evidence; however, a recent study that applied the STROBE standards on studies that reported clinical outcomes on bevacizumab for neovascular AMD demonstrated that although the average reporting score of these studies were lower than that of RCTs on the whole, some studies did indeed obtain higher STROBE scores. 15 Hence, this demonstrates that there are useful studies with considerable evidence-based bearing that are available on this treatment effect outside RCTs and that the pooling of data from well-conducted RCTs and STROBEqualified studies alike are useful under these circumstances.…”

Section: Discussionmentioning

confidence: 99%

“…A group has recently published the use of STROBE criteria for studies on bevacizumab for neovascular AMD until October 2007. 15 In this study, we have extended these findings to include RCTs and STROBE-qualified studies until January 2009. …”

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature

Jyothi

Chowdhury

Elagouz

et al. 2009

Eye

View full text Add to dashboard Cite

Purpose The current medical environment demands that quality health care is delivered at an affordable cost through the use of objective, unbiased clinical data. This study was undertaken to review the current literature on bevacizumab for age-related macular degeneration and its value in determining best clinical practice. Methods Randomised controlled trials (RCTs) and observational studies that met the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria were identified from the current literature for further analysis. Data concerning treatment dosing regimens, response to treatment, complications, and factors influencing outcome and safety were extracted and compiled into a database. Results As of January 2009, there were 5 RCTs that compared the outcomes of bevacizumab to other treatment options and 50 studies that met the STROBE criteria with similar visual and anatomical outcomes between RCTs and observational studies. Although the doses and dosing frequencies varied between the studies, the mean gain in vision at 3 months was þ 7.76±5.4 ETDRS letters (range þ 2 to þ 14.4); an effect that was maintained at 6 months in studies with longer follow-up. Predominantly classic lesions were the most responsive of all lesion subtypes. The complication profiles/rates were similar to those reported with other anti-vascular endothelial agents. Conclusions There is sufficient scientific and statistical evidence to advocate the effective use of OCT-guided administration of intravitreal bevacizumab for neovascular AMD. This is reflected in our study outcome measures that are comparable to findings published from recent well-conducted RCTs on intravitreal ranibizumab at the same time point.

show abstract

Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies

Cited by 77 publications

References 51 publications

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Strengthening the Reporting of Observational Studies in Epidemiology – nutritional epidemiology (STROBE‐nut): An extension of the STROBE statement

Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature

Contact Info

Product

Resources

About